読み込み中
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
前日終値
$7.18
+$0.40 · +5.90%
日中の時刻はETです。市場データは遅延する場合があります。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日中レンジ
現在 $7.18
52週レンジ
現在 $7.18
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
45
適正価値
センチメント
45
まちまち
リスク
75
高リスク
モメンタム
20
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
日中レンジ
現在 $7.18
52週レンジ
現在 $7.18
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 218.5万 USD | — | — | — | — |
| 粗利益 | −218.5万 USD | — | — | — | — |
| 研究開発 | 4492.3万 USD | 4148.8万 USD | 4793.1万 USD | 5419.9万 USD | 5019.2万 USD |
| 販売・一般管理 | 1269.3万 USD | 1571.8万 USD | 1970.6万 USD | 2171万 USD | 2057.3万 USD |
| 営業費用 | 5543.1万 USD | 5974.8万 USD | 6763.7万 USD | 7590.9万 USD | 7076.5万 USD |
| 受取利息 | — | — | — | 116.7万 USD | 1319 USD |
| 支払利息 | — | — | — | — | 7.7万 USD |
| 減価償却費と償却費 | 218.5万 USD | 286.5万 USD | 368.4万 USD | 412.4万 USD | 417.7万 USD |
| 営業利益 | −5761.6万 USD | −5974.8万 USD | −6763.7万 USD | −7590.9万 USD | −7076.5万 USD |
| 純利益 | −5584.4万 USD | −5565.4万 USD | −6272.3万 USD | −7473.3万 USD | −6938.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.00
上昇余地（178.55%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年7月14日 | 1:12 | — | — |
発効済み 2025年7月14日
1:12
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI78.77万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF21.45万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC7.69万0.01%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC1.84万0.00%75.58億 USD0.43%$57.813+0.20%
Dimensional - US Core Equity 2 ETFDFAC400.020.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
